Active, not recruitingPhase 3NCT03974113

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Genzyme, a Sanofi Company
Principal Investigator: Clinical Sciences & Operations
Sanofi
Intervention: Fitusiran(drug)
Enrollment: 32 enrolled
Eligibility: 1-11 years · MALE
Timeline: 2020 – 2026

Study locations (16)

Children's Hospital Los Angeles Site Number : 8400002, Los Angeles, California, United States
Hackensack University Medical Center- Site Number : 8400008, Hackensack, New Jersey, United States
University Hospitals of Cleveland- Site Number : 8400007, Cleveland, Ohio, United States
Penn State Milton S. Hershey Medical Center- Site Number : 8400006, Hershey, Pennsylvania, United States
Investigational Site Number : 1240001, Hamilton, Ontario, Canada
Investigational Site Number : 1240002, Ottawa, Ontario, Canada
Investigational Site Number : 3560006, Bangalore, India
Investigational Site Number : 3560002, Mumbai, India
Investigational Site Number : 3560001, Pune-411011, India
Investigational Site Number : 3560004, Vellore, India
Investigational Site Number : 3800002, Florence, Italy
Investigational Site Number : 3800001, Milan, Italy
Investigational Site Number : 7240002, Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7920001, Adana, Turkey (Türkiye)
Investigational Site Number : 7920002, Istanbul, Turkey (Türkiye)
+1 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03974113 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials